Clinical Trial Update: Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma. [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of TQB2223 in combination with AK105 for advanced hepatocellular carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• AK105 (anti-PD-1 monoclonal antibody)
• TQB2223

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Advanced Hepatocellular Carcinoma | Phase 1 | Status: TERMINATED